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Introduction.The aim of our workwas to investigate the causal connection betweenM1 andM2macrophage phenotypes occurrence
and prostate cancer, their correlation with tumor extension (ECE), and biochemical recurrence (BR). Patient andMethods. Clinical
and pathological data were prospectively gathered from 93 patients treated with radical prostatectomy. Correlations of commonly
used variables were evaluated with uni- andmultivariate analysis.The relationship betweenM1 andM2 occurrence and BRwas also
assessed with Kaplan-Meier survival analysis. Results. Above all in 63.4% there was a M2 prevalence. M1 occurred more frequently
in OC disease, while M2 was more represented in ECE. At univariate analysis biopsy and pathologic GS and M2 were statistically
correlated with ECE. Only pathologic GS andM2 confirmed to be correlated with ECE. According tomacrophage density BCR free
survival curves presented a statistically significant difference. When we stratified our population for M1 and M2,we did not find
any statistical difference among curves. At univariate analysis GS, pTNM, and positive margins resulted to be significant predictors
of BCR, while M1 and M2 did not achieve the statistical significance. At multivariate analysis, only GS and pathologic stage were
independent predictors of BR.Conclusion. In our study patientswith higher density ofMcountwere associatedwith poor prognosis;
M2 phenotype was significantly associated with ECE.
1. Introduction
Several epidemiologic studies support the opinion that
chronic inflammatory diseases are frequently associated with
increased risk of various human cancers, even up to 25% of
them [1, 2].
Prostate cancer (PCa) represents one of the most com-
mon cancers and the second leading cause of cancer-related
death in men in the United States [3]. Actually there is a
substantial epidemiological evidence that chronic inflamma-
tion is associated with PCa [4] and many studies aimed to
investigate the causal connection between inflammation and
PCa.
It has been recently observed that proliferative inflam-
matory atrophy (PIA) lesions are strictly related to chronic
prostatic inflammation, and histological cellular transitions
have been noted between areas of PIA and high-grade
prostate intraepithelial neoplasia (HGPIN), and furthermore
between PIA and PCa [5]. A key role of the PIA lesion
is the presence of leukocyte infiltration, with the majority
of cells belonging to the monocyte-macrophages lineage.
Tumor-associated macrophages (TAMs) are a significant
component of the inflammatory cell infiltrates in prostate
cancer. Mononuclear cells and/or polymorphonuclear cells
in both epithelial and stromal compartments promote car-
cinogenesis with their ability to communicate via a complex
network of intercellular signalling pathways mediated by
proinflammatory cytokines, their receptors, and cell surface
adhesionmolecules. TAMsmay have both tumor stimulatory
and/or -inhibitory properties, probably because they can,
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by mechanisms largely unknown, differentiate into either
cytotoxic (M1) or tumor growth promoting (M2) states.
In several murine cancer models including chemically and
genetically induced primary lung tumors, prostate tumors,
colon xenografts, and lung metastases, TAMs expressed M2
early during tumorigenesis [6].
The aim of our work was to investigate the causal
connection between M1 and M2 phenotype macrophages
occurrence with PCa and to evaluate their correlation with
clinic-pathological commonly used variables and survival.
2. Material and Methods
In our tertially referral center we routinely store in a specific
database clinical and pathological data of patient undergoing
radical prostatectomy (RP). In order to study a greater
amount of neoplastic tissue and to better locate prostate
inflammation at the pathological examination, we decided to
prospectively select 93 consecutive patients with stage cT2b-
c PCa undergoing RP from January 2000 to December 2011.
Clinical stage assessment was routinely made by digital rectal
examination at the visit, transrectal ultrasound at the time
of the biopsy, and endorectal coil magnetic resonance for
evaluating local extension. CT scan and bone scintigraphy
were required for patients with PSA ≥ 20 ng/mL and GS ≥ 7.
All patients received anterograde RP according to our
previously published technique [7]. The follow-up schedule
included serum PSA assay every 3 months for the first year,
then every 6 months for the following 2 years, and yearly
thereafter. Biochemical recurrence (BCR) was defined as evi-
dence of PSA> 0.2 ng/mL on two consecutivemeasurements.
2.1. Statistical Analysis. Statistical analysis was performed
using StatView software. Univariate analysis was carried out
as follows: Student’s 𝑡-test was used comparing continuous
parametric variables, Mann Whitney test was used compar-
ing continuous nonparametric variables, and Pearson chi
square test was used comparing nominal variables.
The risk of ECE, related to the preoperative variables
analyzed, was evaluated using the logistic regression model,
and odds ratios and risk ratios were calculated.
In order to establish the correlation between
macrophages phenotype and prognosis, the BCR-free
survival rate was estimated by the Kaplan-Meier method.
Statistical significance was verified by the log-rank test.
2.2. Tissue Specimens and Immunohistochemistry. All
specimens were obtained from the archives of formalin-
fixed, paraffin-embedded tissue blocks. Haematoxylin-eosin
stained sections from each histological specimen were
reevaluated to confirm the histological diagnosis of PCa, for
the Gleason grade [8] for detecting perineural invasion, and
for surgical margin status. All cases were also reevaluated
regarding the World Health Organization (WHO) 2004
classification [9] and pathological 𝑇 staging was performed
[10]. In addition, a representative tissue block was selected
for further analysis. The following immunohistochemical
markers were evaluated: CD68 and CD163. The stains for
Figure 1: Presence of both M1 and M2 that were characterized by a
red cytoplasm due to chromogen FAST RED for CD68 (M1) or with
a brown cytoplasm due to chromogen diaminobenzidine (DAB) for
CD163 (M2).
CD68 and CD163 were considered positive when there was a
strong granular cytoplasmic or cytoplasmic and membrane
staining patterns in cells of monocyte/macrophages lineage.
2.3. Slide Grading. Macrophages were quantified by system-
atically screening the entire carcinoma area at low mag-
nification using a 2,5x or 5x lens and selecting the areas
with the highest density of macrophages and by counting
them. M1 and M2 are distinguished by two different primary
antibodies: anti-CD163 (for M2) and anti-CD68 (for M1) and
two different chromogens: chromogen diaminobenzidine
(DAB) for CD163 (M2, color brown) and chromogen FAST
RED for CD68 (M1, color red). Therefore, we were able to
recognize easily the two types of macrophages due to this
double coloration (brown macrophages or M2 versus red
macrophages orM1), and consequently we were able to count
separately M1 and M2. We systematically screened the entire
carcinoma area at low magnification, and in this way we
selected the areas rich with macrophages (called: hot spot).
After that, both M1 and M2 macrophages were manually
counted at highmagnification (Figure 1). Finally, the mean of
both the number of M1 macrophages and M2 macrophages
in these three hot spots was obtained. All counting was
performed by one investigator (MRR) unaware of clinical
data.
3. Results
Clinical and pathological characteristics of 93 patients
included in our study are listed in Table 1.
Our patients presented median (IQR) preoperative PSA
of 7.6 (1.01–86.8) and a prevalence of biopsy GS 6 (53.8%).
Mean (SD) follow-up time after radical prostatectomy was
50.4 months (19.2). BCR occurred in 23 patients (24.7%)
with a mean (SD) follow-up period of 26.3 (25.2) months.
Among them 11 patients underwent delayed radiotherapy
and 12 patients underwent palliative hormone therapy during
follow-up period.
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Table 1: Clinical presentation, pathologic findings, and follow-up of the 93 patients.
Macrophages population Total of patients M1 M2
𝑛 (%) 93 34 (36.6) 59 (63.4)
Count in three hot spots Mean (median) 12.06 (6) 17.18 (10)
Density of macrophages M1 and M2 in three
hot spots according to median number
43 below median number
50 above median number
Preoperative variables
Age (yy) median (IQR) 67 (45–75) 64 (55–74) 67 (45–75)
Total PSA (ng/mL) median (IQR) 7.6 (1.0–86.8) 8.3 (2.5–47.7) 7.0 (1–76.8)
Biopsy Gleason score 𝑛 (%)
6 50 (53.8) 19 (55.9) 31 (52.6)
7 28 (30.1) 12 (35.3) 16 (27.1)
8–10 15 (16.1) 3 (8.8) 12 (20.3)
Postoperative variables
Organ confine disease (OC) 𝑛 (%) 33 (35.5) 19 (55.9) 14 (23.8)
Extracapsular extension (ECE) 𝑛 (%) 60 (64.5) 15 (44.1) 45 (76.2)
TNM stage 𝑛 (%)
T2 33 (35.5) 19 (55.9) 14 (23.8)
T3a 35 (37.6) 7 (20.6) 28 (47.4)
T3b 23 (24.8) 8 (23.5) 15 (25.4)
T4 2 (2.1) 0 2 (3.4)
Pathologic Gleason score 𝑛 (%)
6 30 (32.2) 13 (38.2) 17 (28.8)
7 40 (43) 16 (47.1) 24 (40.7)
8–10 23 (24.8) 5 (14.7) 18 (30.5)
Lymph node involvement 𝑛 (%) 5 (5.3) 2 (5.9) 3 (5.1)
Positive surgical margin 𝑛 (%) 11 (11.8) 2 (5.9) 9 (15.2)
Follow-up (months) mean (SD) 50.4 (19.2) 55.5 (21.2) 47.6 (16.3)
Biochemical recurrence 𝑛 (%) 23 (24.7) 7 (20.6) 16 (27.1)
At the final anatomopathological evaluation 33 patients
(35.5%) presented organ confined disease (OC), while in 60
pts (64.5%) there was ECE and positive surgical margins were
found in 11 patients (11.8%). Patients with ECE presented
higher prevalence of GS 7 to 8–10 and higher prevalence of
PSA > 10 ng/mL with respect to the OC disease patients.
The macrophages prevalence is reported in Table 1 as
follow: in 34 (36.6%) patients a higher prevalence of M1
was found, while in 59 (63.4%) patients there was a higher
prevalence of M2. Mean (median) macrophage count of M1
and M2 in the three hot spots was 12.06 (6.0) and 17.18 (10.0),
respectively.
M1 occurred more frequently in OC PCa, especially with
GS 6 to 7 (mean number 18.6, median 11.6), whileM2 resulted
to be more represented in PCa with ECE and GS 7 to 8-10
(mean number 20.2, median 10).
When we correlated M1-M2 ratio to GS, biopsy cores,
stage, and BCR at Student’s 𝑡-test and Pearson 𝜒2 test, we
found statistical correlation only with stage (𝑃 = 0.004).
Moreover, at univariate analysis for ECE, pathological GS and
M2 phenotype were statistically correlated with extracapsular
extension (0.029, 0.0001, and 0.0079, resp.).
On the contrary, we did not find any statistical correlation
between BCR and M1-M2 ratio, even if patients with higher
prevalence of M1 phenotype presented better results.
At logistic regression analysis only specimen GS and M1-
M2 ratio confirmed to be statistically correlated with ECE
(𝑃 = 0.05, RR 10.65, and 95% CI 1.11–102.26 and 𝑃 = 0.03,
RR 0.295, and 95% CI 0.09–0.89, resp.) (see Table 2).
Moreover, at univariate analysis biopsy GS, pathological
GS, pTNM, positive surgical margins, and high density of
macrophages in three hot spots resulted to be independently
predictive of BCR (𝑃 = 0.0009, 0.0006, and 0.0147, resp.),
while substratification in M1 and M2 did not achieve the
statistical significance. At Cox multivariable analysis only
pathologic GS and stage resulted to be independent predic-
tors of BCR (𝑟 = 19.146, 𝑃 = 0.02 and 𝑟 = 3.43, 𝑃 = 0.05,
resp.) (see Table 3).
At the Kaplan-Meier survival analysis, the 36 and 60
months BR free survival rate for the global population
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Table 2: Univariate (Pearson 𝜒2 test, 𝑡-test, and Mann Whitney test) and multivariate (logistic regression) analysis of common variables to
predict extracapsular extension (ECE) of PCa.
Variables Univariate analysis
𝑃 value
Multivariate analysis
𝑃 value Risk ratio 95% CI
Preoperative PSA Ns Not included in analysis
Biopsy GS > 7 0.029 0.07 4.21 1.10–19.62
Anatomopathological GS > 7 0.0001 0.05 10.65 1.11–102.26
Lymphnode invasion Ns Not included in analysis
M1/M2 0.0079 0.03 0.295 0.09–0.89
Table 3: Univariate (Pearson 𝜒2 test, MannWhitney Test, and 𝑡-test) and multivariate (Cox proportional hazard model) analysis of common
variables to predict BCR.
Variables Univariate analysis 𝑃 value Multivariate analysis
𝑃 value Risk ratio 95% CI
Preoperative PSA Ns —
Biopsy GS > 7 0.0009 0.07 2.26 1.1–10.47
Anatomopathological GS > 7 0.0006 0.02 16.04 1.44–177.9
Pathological stage 0.0147 0.03 3.43 1.09–11.8
Lymphnode invasion Ns —
Status Ns —
Surgical margin status Ns —
High density of macrophages M1
and M2 in three hot spots (above
median value)
0.05 0.09 2.53 1.6–9.67
M1-2 phenotype Ns —
resulted to be 84.6% and 72.5%, respectively. According to
macrophage density, BCR free survival curves at the Kaplan-
Meier analysis were 94.4 versus 74.0 and 85.1 versus 62.2 at
36 and 60 months, respectively, with a statistically significant
difference among the curves (𝑃 = 0.05) (Figure 2).
Moreover, when we stratified our patients for M1 and
M2 macrophage phenotypes, we did not find any statistical
difference among BCR free survival curves (log rank 𝑃 = 𝑛𝑠),
although we observed that patients with prevalence of M2
macrophages showed a trend toward worst BCR free survival
rates at 36 and 60 months compared to patients with M1
prevalence (78.2 versus 94.1 and 71.0 versus 77.4, resp.) (see
Figure 3). When we analyzed survival curves for the category
of patients with only ECE, among them, stratification for M1
andM2macrophage phenotype did not allow us to establish a
significant correlation with prognosis, although even in this
instance patients with M2 phenotype prevalence confirmed
to have a slightly worse prognosis.
4. Discussion
To date several clinicopathological factors have been reported
as prognostic factors, but few studies have been reported on
anticancer immune response by the host.
Prostate is constituted by epithelium and surrounding
stroma, which itself consists of smooth muscle, extracellular
matrix, and inflammatory cells. Inflammation has been thor-
oughly described as a key player in PCa, and among various
inflammatory cell population, macrophages have been recog-
nized as one of themajor components. Chronic inflammation
characterized by sustained tissue damage, damage induced
cellular proliferation, and tissue repair have been analyzed
in order to explain prostatic carcinogenesis, demonstrating
a strong association between chronic prostatic inflammation,
premalignant, and malignant changes in the prostatic epithe-
lium in a prospective five years follow-up study on needle
biopsy specimens [4].Moreover,Nonomura et al. noticed that
TAM infiltration was significantly correlated with serumPSA
level, GS, or stage among the clinicopathological factors in
prostate needle biopsy specimens [11].
Shimura et al. studied the association between TAM
infiltration and disease-free survival after RP using whole
mount sections, demonstrating that disease-free survival is
significantly shorter for patients with a high level of TAMs
than for those with a low level [12].
Macrophages are likely to encounter factors that most
frequently polarise them toward M1 and M2 subtype
macrophages, especially TAMs that express selected M2
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Figure 2: Biochemical recurrence (BCR) free survival curves at the
Kaplan-Meier analysis of our 93 patients study population based on
median number of macrophages. The blue line represents BCR free
survival curve of patients with low density of macrophages M1 and
M2 in three hot spots (n∘ of macrophages <median number), while
the red line represents those with high density ofM1 andM2 in three
hot spots (>median number). BCR free survival rates at 36 and 60
months were 94.4 versus 74.0 and 85.1 versus 62.2, respectively, 𝑃 =
0.05.
protumoural functions, tumor progression, and metastasis
[13].
In our study we observed that higher density of
macrophage was statistically associated to poorer prognosis
(𝑃 = 0.05, Figure 2).Moreover we found higher prevalence of
M2macrophage phenotype, which resultedmore represented
in PCa with ECE (𝑃 = 0.0079) and GS 7 to 8–10 and pT3a
stage (𝑃 = 𝑛𝑠). Our patients expressing more M2 phenotype
frequently presented ECE and BCR, even if it was not
confirmed at our statistical analysis. According to previous
data published in the literature, TAMs generally exhibit
an M2 phenotype known to promote angiogenesis, tumor
growth, and metastasis [14]. To corroborate our preliminary
results, in male mice TAM polarization in primary tumors
at four distinct stages including PIN, well-differentiated,
moderately differentiated, and poorly differentiated PCa has
been examined [15].
In comparison to our global series of prostatectomies
performed in our referral center as previously reported [7],
we noticed in these 93 patient a slight higher incidence of
extracapsular disease and GS 7. This was certainly due to
our necessity to definitely locate macrophages in the prostate
specimen at the final pathological evaluation. Indeed even in
the literature high TAMcount is statistically found in patients
with higher stages (extracapsular extension) and grades (GS
> 7) [11]. Even if it could be a limit of the study, our study
population on the border between OC and ECE disease may
be anyway extremely indicative for macrophage evaluation.
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Figure 3: Biochemical recurrence (BCR) free survival curves at the
Kaplan-Meier analysis of our 93 patients study population stratified
for M1 and M2 macrophages prevalence. The blue line represents
BCR free survival curve of patients withM1macrophage prevalence,
while the red line represents those withM2macrophage prevalence.
BCR free survival rates at 36 and 60 months were 94.1 versus 78.2
and 77.4 versus 71.0, respectively.
In addition to our preliminary results, further analysis on
larger series of patients will allow us to better define M1-2
phenotype role in tumour aggressiveness and outcome.
5. Conclusion
It has become increasingly clear that TAMs are active players
in the tumor aggressiveness. This is a preliminary study
in which we laid down groundwork for further studies.
In our study population with clinically localized PCa with
stage cT2b-c, we found correlation between highmacrophage
infiltration and unfavorable items after RP. Moreover, M2
macrophage phenotype was significantly associated with
extracapsular extension, even if this phenotype prevalence
was not capable at the moment to predict BCR. Macrophage
phenotype has demonstrated to be fascinating and valuable
to rationalize a more aggressive adjuvant approach, even if
further studies are needed to verify it.
Conflict of Interests
The authors declare that there is no conflict of interests
regarding the publication of this paper.
References
[1] M. Philip, D. A. Rowley, and H. Schreiber, “Inflammation as
a tumor promoter in cancer induction,” Seminars in Cancer
Biology, vol. 14, no. 6, pp. 433–439, 2004.
6 BioMed Research International
[2] H. Lu, W. Ouyang, and C. Huang, “Inflammation, a key event
in cancer development,” Molecular Cancer Research, vol. 4, no.
4, pp. 221–233, 2006.
[3] A. Jemal, R. Siegel, E. Ward, Y. Hao, J. Xu, and M. J. Thun,
“Cancer statistics, 2009,” CA Cancer Journal for Clinicians, vol.
59, no. 4, pp. 225–249, 2009.
[4] G. T. MacLennan, R. Eisenberg, R. L. Fleshman et al., “The
influence of chronic inflammation in prostatic carcinogenesis:
a 5-year followup study,” Journal of Urology, vol. 176, no. 3, pp.
1012–1016, 2006.
[5] A. M. De Marzo, V. L. Marchi, J. I. Epstein, and W. G.
Nelson, “Proliferative inflammatory atrophy of the prostate:
implications for prostatic carcinogenesis,” American Journal of
Pathology, vol. 155, no. 6, pp. 1985–1992, 1999.
[6] E. F. Redente, L. D. Dwyer-Nield, D. T. Merrick et al., “Tumor
progression stage and anatomical site regulate tumor-associated
macrophage and bonemarrow-derivedmonocyte polarization,”
American Journal of Pathology, vol. 176, no. 6, pp. 2972–2985,
2010.
[7] M. Carini, L. Masieri, A. Minervini, A. Lapini, and S. Serni,
“Oncological and functional results of antegrade radical retrop-
ubic prostatectomy for the treatment of clinically localized
prostate cancer,” European Urology, vol. 53, no. 3, pp. 554–563,
2008.
[8] J. I. Epstein, W. C. Allsbrook Jr., M. B. Amin et al., “The 2005
International Society of Urological Pathology (ISUP) consensus
conference on Gleason grading of prostatic carcinoma,” Amer-
ican Journal of Surgical Pathology, vol. 29, no. 9, pp. 1228–1242,
2005.
[9] J. N. Eble, G. Sauter, J. I. Epstein, and I. A. Sesterhenn, World
Health Organization Classification of Tumours. Pathology and
Genetics of Tumours of the Urinary System and Male Genital
Organs, IARC Press, Lyon, France, 2004.
[10] AJCC, Cancer Staging Manual, Springer, New York, NY, USA,
7th edition, 2010.
[11] N.Nonomura,H. Takayama,M.Nakayama et al., “Infiltration of
tumour-associated macrophages in prostate biopsy specimens
is predictive of disease progression after hormonal therapy for
prostate cancer,” BJU International, vol. 107, no. 12, pp. 1918–
1922, 2011.
[12] S. Shimura, G. Yang, S. Ebara, T. M. Wheeler, A. Frolov, and
T. C. Thompson, “Reduced infiltration of tumor-associated
macrophages in human prostate cancer: associationwith cancer
progression,” Cancer Research, vol. 60, no. 20, pp. 5857–5861,
2000.
[13] A. Sica, T. Schioppa, A. Mantovani, and P. Allavena, “Tumour-
associated macrophages are a distinct M2 polarised population
promoting tumour progression: potential targets of anti-cancer
therapy,” European Journal of Cancer, vol. 42, no. 6, pp. 717–727,
2006.
[14] A. Sica, P. Larghi, A. Mancino et al., “Macrophage polarization
in tumour progression,” Seminars in Cancer Biology, vol. 18, no.
5, pp. 349–355, 2008.
[15] K. Raina, R. P. Singh, R. Agarwal, and C. Agarwal, “Oral grape
seed extract inhibits prostate tumor growth and progression in
TRAMP mice,” Cancer Research, vol. 67, no. 12, pp. 5976–5982,
2007.
Submit your manuscripts at
http://www.hindawi.com
Stem Cells
International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
MEDIATORS
INFLAMMATION
of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Behavioural 
Neurology
Endocrinology
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Disease Markers
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
BioMed 
Research International
Oncology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Oxidative Medicine and 
Cellular Longevity
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
PPAR Research
The Scientific 
World Journal
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Immunology Research
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Journal of
Obesity
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
 Computational and  
Mathematical Methods 
in Medicine
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Research and Treatment
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Parkinson’s 
Disease
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com
